Epidemiology, pathology and treatment of non-follicular indolent lymphomas

References

• Adult non-Hodgkin's lymphoma treatment, 17 December 2007 –[cited 15 January 2008]. Available from www.cancer. gov
   Google Scholar
• Seng J E, Peterson B A. Indolent B-cell non-Hodgkin's lymphomas. Oncology 1997; 11: 1883–1894
   PubMedGoogle Scholar
• Turesson I, Linet M S, Björkholm M, Kristinsson S Y, Goldin L R, Caporaso N E, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964–2003. Int J Cancer 2007; 121: 2260–2266
   PubMed Web of Science ®Google Scholar
• Landgren O, Björkholm M, Montgomery S M, Hjalgrim H, Sjöberg J, Goldin L R, et al. Personal and family history of autoimmune diabetes mellitus and susceptibility to young-adult-onset Hodgkin lymphoma. Int J Cancer 2006; 118: 449–452
   PubMed Web of Science ®Google Scholar
• Landgren O, Engels E A, Caporaso N E, Gridley G, Mellemkjaer L, Hemminki K, et al. Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. Blood 2006; 108: 292–296
   PubMed Web of Science ®Google Scholar
• Landgren O, Linet M S, McMaster M L, Gridley G, Hemminki K, Goldin L R. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006; 118: 3095–3098
   PubMed Web of Science ®Google Scholar
• Landgren O, Rapkin J S, Caporaso N E, Mellemkjaer L, Gridley G, Goldin L R, et al. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood 2007; 109: 2198–2201
   PubMed Web of Science ®Google Scholar
• Mellemkjaer L, Andersen V, Linet M S, Gridley G, Hoover R, Olsen J H. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 761–768
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Rai K R, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 805–815
   Web of Science ®Google Scholar
• Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007; 109: 259–270
   PubMed Web of Science ®Google Scholar
• Miklos J A, Swerdlow S H, Bahler D W. Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V(H) genes show frequent use of V1-69 with distinctive CDR3 features. Blood 2000; 95: 3878–3884
   PubMed Web of Science ®Google Scholar
• Marasca R, Vaccari P, Luppi M, Zucchini P, Castelli I, Barozzi P, et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol 2001; 159: 253–261
   PubMed Web of Science ®Google Scholar
• Algara P, Mateo M S, Sanchez-Beato M, Mollejo M, Navas I C, Romero L, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002; 99: 1299–1304
   PubMed Web of Science ®Google Scholar
• Camacho F I, Algara P, Rodríguez A, Ruíz-Ballesteros E, Mollejo M, Martínez N, et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood 2003; 101: 4042–4046
   PubMed Web of Science ®Google Scholar
• Stamatopoulos K, Belessi C, Papadaki T, Kalagiakou E, Stavroyianni N, Douka V, et al. Immunoglobulin heavy- and light-chain repertoire in splenic marginal zone lymphoma. Mol Med 2004; 10: 89–95
   PubMed Web of Science ®Google Scholar
• Goldin L R, Landgren O, McMaster M L, Gridley G, Hemminki K, Li X, et al. Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. Cancer Epidemiol Biomarkers Prev 2005; 14: 2402–2406
   PubMed Web of Science ®Google Scholar
• Goldin L R, Pfeiffer R M, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood 2004; 104: 1850–1854
   PubMed Web of Science ®Google Scholar
• Goldin L R, Pfeiffer R M, Gridley G, Gail M H, Li X, Mellemkjaer L, et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer 2004; 100: 1902–1908
   PubMed Web of Science ®Google Scholar
• Marti G E, Rawstron A C, Ghia P, Hillmen P, Houlston R S, Kay N, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005; 130: 325–332
   PubMed Web of Science ®Google Scholar
• Rawstron A C, Bennett F L, O'Connor S J, Kwok M, Fenton J A, Plummer M, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med Aug 7, 2008; 359(6)575–583
   PubMed Web of Science ®Google Scholar
• Landgren O, Kyle R A. Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases. Br J Haematol 2007; 139: 717–723
   PubMed Web of Science ®Google Scholar
• Thomas R, Ribeiro I, Shepherd P, Johnson P, Cook M, Lakhani A, et al. Spontaneous clinical regression in chronic lymphocytic leukaemia. Br J Haematol 2002; 116: 341–345
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Rai K R, Sawitsky A, Cronkite E P, Chanana A D, Levy R N, Pasternack B S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234
   PubMed Web of Science ®Google Scholar
• Binet J L, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson B D, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008; 12: 5446–5556
   Web of Science ®Google Scholar
• Tsimberidou A M, Wen S, O'Brien S, McLaughlin P, Wierda W G, Ferrajoli A, et al. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2007; 25: 4648–4656
   PubMed Web of Science ®Google Scholar
• Arcaini L, Paulli M, Boveri E, Magrini U, Lazzarino M. Marginal zone-related neoplasms of splenic and nodal origin. Haematologica 2003; 88: 80–93
   PubMed Web of Science ®Google Scholar
• Ferreri A J, Zucca E. Marginal-zone lymphoma. Crit Rev Oncol Hematol 2007; 63: 245–256
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Coiffier B. Management of marginal zone lymphomas. Curr Treat Options Oncol 2006; 7: 213–222
   PubMedGoogle Scholar
• Cualing H, Steele P, Zellner D. Blastic transformation of splenic marginal zone B-cell lymphoma. Arch Pathol Lab Med 2000; 124: 748–752
   PubMed Web of Science ®Google Scholar
• Oscier D, Owen R, Johnson S. Splenic marginal zone lymphoma. Blood Rev 2005; 19: 39–51
   PubMed Web of Science ®Google Scholar
• Audouin J, Le Tourneau A, Molina T, Camilleri-Broët S, Adida C, Comperat E, et al. Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. Br J Haematol 2003; 122: 404–412
   PubMed Web of Science ®Google Scholar
• Camacho F I, Mollejo M, Mateo M S, Algara P, Navas C, Hernández J M, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol 2001; 25: 1268–1276
   PubMed Web of Science ®Google Scholar
• Parsonnet J, Isaacson P G. Bacterial infection and MALT lymphoma. N Engl J Med 2004; 350: 213–215
   PubMed Web of Science ®Google Scholar
• Dallenbach F E, Coupland S E, Stein H. Marginal zone lymphomas: extranodal MALT type, nodal and splenic. Pathologe 2000; 21: 162–177
   PubMed Web of Science ®Google Scholar
• Levy M, Copie-Bergman C, Traulle C, Lavergne-Slove A, Brousse N, Flejou J F, et al. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. Am J Gastroenterol 2002; 97: 292–297
   PubMed Web of Science ®Google Scholar
• Liu H, Ye H, Ruskone-Fourmestraux A, De Jong D, Pileri S, Thiede C, et al. t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286–1294
   PubMed Web of Science ®Google Scholar
• Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005; 23: 8018–8024
   PubMed Web of Science ®Google Scholar
• Yeh K H, Kuo S H, Chen L T, Mao T L, Doong S L, Wu M S, et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood 2005; 106: 1037–1041
   PubMed Web of Science ®Google Scholar
• Martinelli G, Laszlo D, Ferreri A J, Pruneri G, Ponzoni M, Conconi A, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979–1983
   PubMed Web of Science ®Google Scholar
• Saadoun D, Suarez F, Lefrere F, Valensi F, Mariette X, Aouba A, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?. Blood 2005; 105: 74–76
   PubMed Web of Science ®Google Scholar
• Franco V, Florena A M, Iannitto E. Splenic marginal zone lymphoma. Blood 2003; 101: 2464–2472
   PubMed Web of Science ®Google Scholar
• Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008; 22: 487–495
   PubMed Web of Science ®Google Scholar
• Kent S A, Variakojis D, Peterson L C. Comparative study of marginal zone lymphoma involving bone marrow. Am J Clin Pathol 2002; 117: 698–708
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Felman P, Berger F, Dumontet C, Arnaud P, Hequet O, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma 2002; 3: 41–47
   PubMedGoogle Scholar
• Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006; 107: 4643–4649
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Felman P, Callet-Bauchu E, Traverse-Glehen A, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003; 4: 95–103
   PubMed Web of Science ®Google Scholar
• Chacón J I, Mollejo M, Muñoz E, Algara P, Mateo M, Lopez L, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002; 100: 1648–1654
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis G A, Dimopoulou M N, Vassilakopoulos T P, Kyrtsonis M C, Korkolopoulou P, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2007; 25: 127–131
   PubMed Web of Science ®Google Scholar
• Tsimberidou A M, Catovsky D, Schlette E, O'Brien S, Wierda W G, Kantarjian H, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006; 107: 125–135
   PubMed Web of Science ®Google Scholar
• Arcaini L, Paulli M, Boveri E, Vallisa D, Bernuzzi P, Orlandi E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004; 100: 107–115
   PubMed Web of Science ®Google Scholar
• Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo M G, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003; 102: 996–999
   PubMed Web of Science ®Google Scholar
• Zuckerman E, Zuckerman T, Levine A M, Douer D, Gutekunst K, Mizokami M, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997; 127: 423–428
   PubMed Web of Science ®Google Scholar
• Suarez F, Lefrere F, Besson C, Hermine O. Splenic lymphoma with villous lymphocytes, mixed cryoglobulinemia and HCV infection: deciphering the role of HCV in B-cell lymphogenesis. Dig Liver Dis 2007; 39: S32–S37
   PubMedGoogle Scholar
• Silvestri F, Pipan C, Barillari G, Zaja F, Fanin R, Infanti L, et al. Prevalence of hepatitis C virus infections in patients with lymphoproliferative disorders. Blood 1996; 87: 4296–4301
   PubMed Web of Science ®Google Scholar
• Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005; 23: 468–473
   PubMed Web of Science ®Google Scholar
• Hermine O, Lefrere F, Bronowicki J P, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of Hepatitis C virus infection. N Engl J Med 2002; 347: 89–94
   PubMed Web of Science ®Google Scholar
• Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon P A, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000; 95: 1950–1956
   PubMed Web of Science ®Google Scholar
• Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, et al. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol 2007; 136: 301–304
   PubMed Web of Science ®Google Scholar
• Nathwani B N, Anderson J R, Armitage J O, Cavalli F, Diebold J, Drachenberg M R, et al. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1999; 17: 2486–2492
   PubMed Web of Science ®Google Scholar
• Traverse-Glehen A, Felman P, Callet-Bauchu E, Gazzo S, Baseggio L, Bryon P A, et al. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology 2006; 88: 162–173
   Web of Science ®Google Scholar
• Oh S Y, Ryoo B Y, Kim W S, Kim K, Lee J, Kim H J, et al. Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol 2006; 86: 781–786
   Web of Science ®Google Scholar
• Koh L P, Lim L C, Thng C H. Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol 2000; 17: 225–228
   PubMed Web of Science ®Google Scholar
• Mollejo M, Camacho F I, Algara P, Ruiz-Ballesteros E, García J F, Piris M A. Nodal and splenic marginal zone B cell lymphomas. Hematol Oncol 2005; 23: 108–118
   PubMed Web of Science ®Google Scholar